First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial.


Journal

Circulation
ISSN: 1524-4539
Titre abrégé: Circulation
Pays: United States
ID NLM: 0147763

Informations de publication

Date de publication:
21 06 2022
Historique:
pubmed: 5 5 2022
medline: 24 6 2022
entrez: 4 5 2022
Statut: ppublish

Résumé

Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally. We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death. Randomly assigned patients had a mean age of 55 years (interquartile range, 46-64) and left ventricular ejection fraction of 40% (interquartile range, 30%-49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35-0.96]; Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies. URL: https://www. gov; Unique identifier: NCT02848781.

Sections du résumé

BACKGROUND
Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally.
METHODS
We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death.
RESULTS
Randomly assigned patients had a mean age of 55 years (interquartile range, 46-64) and left ventricular ejection fraction of 40% (interquartile range, 30%-49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35-0.96];
CONCLUSIONS
Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies.
REGISTRATION
URL: https://www.
CLINICALTRIALS
gov; Unique identifier: NCT02848781.

Identifiants

pubmed: 35507499
doi: 10.1161/CIRCULATIONAHA.122.060039
doi:

Banques de données

ClinicalTrials.gov
['NCT02848781']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

1839-1849

Commentaires et corrections

Type : CommentIn

Auteurs

Roderick Tung (R)

The University of Chicago, Center for Arrhythmia Care, Pritzker School of Medicine, IL (R.T., D.Y.S., S.A.B.).
Guangdong Provincial People's Hospital, China (R.T., Y.X., H.L.).
Department of Cardiology, Sir Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China (R.T.).

Yumei Xue (Y)

Guangdong Provincial People's Hospital, China (R.T., Y.X., H.L.).

Minglong Chen (M)

The First Affiliated Hospital of Nanjing Medical University, China (M.C., K.G.).

Chenyang Jiang (C)

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.J., R.J.).

Dalise Y Shatz (DY)

The University of Chicago, Center for Arrhythmia Care, Pritzker School of Medicine, IL (R.T., D.Y.S., S.A.B.).

Stephanie A Besser (SA)

The University of Chicago, Center for Arrhythmia Care, Pritzker School of Medicine, IL (R.T., D.Y.S., S.A.B.).

Hongde Hu (H)

Department of Cardiology, West China Hospital, Sichuan University, Chengdu (H.H., J.J.).

Fa-Po Chung (FP)

Taipei Veterans General Hospital, National Yang Ming Chiao Tung University, Taiwan (F.-P.C.).

Shiro Nakahara (S)

Dokkyo Medical University Saitama Medical Center, Japan (S.N., Y.H.).

Young-Hoon Kim (YH)

Division of Cardiology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea (Y.-H.K., J.-I.C.).

Lishui Shen (L)

Fuwai Hospital, Arrhythmia Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing (L.S., E.L., Y.Y.).

Er'peng Liang (E)

Fuwai Hospital, Arrhythmia Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing (L.S., E.L., Y.Y.).

Hongtao Liao (H)

Guangdong Provincial People's Hospital, China (R.T., Y.X., H.L.).

Kai Gu (K)

The First Affiliated Hospital of Nanjing Medical University, China (M.C., K.G.).

Ruhong Jiang (R)

Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China (C.J., R.J.).

Jian Jiang (J)

Department of Cardiology, West China Hospital, Sichuan University, Chengdu (H.H., J.J.).

Yuichi Hori (Y)

Dokkyo Medical University Saitama Medical Center, Japan (S.N., Y.H.).

Jong-Il Choi (JI)

Division of Cardiology, Department of Internal Medicine, Korea University Medical Center, Seoul, Korea (Y.-H.K., J.-I.C.).

Akiko Ueda (A)

Division of Advanced Arrhythmia Management, Kyorin University Hospital, Japan (A.U.).

Yuki Komatsu (Y)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Japan (Y.K., A.N.).

Shuichiro Kazawa (S)

Tokyo Medical University, Japan (S.K.).

Kyoko Soejima (K)

Department of Cardiovascular Medicine, Kyorin University Hospital, Japan (K.S.).

Shih-Ann Chen (SA)

Cardiovascular Center, Taichung Veterans General Hospital, Taichung, Taiwan (S.-A.C.).

Akihiko Nogami (A)

Department of Cardiology, Faculty of Medicine, University of Tsukuba, Japan (Y.K., A.N.).

Yan Yao (Y)

Fuwai Hospital, Arrhythmia Center, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing (L.S., E.L., Y.Y.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH